Piramal acquires molecular imaging portfolio of Bayer

Piramal Healthcare Ltd [stockquote]PIRHEALTH[/stockquote] has acquired the molecular imaging development portfolio of Bayer Pharma AG.

Its newly created subsidiary called Piramal Imaging SA has entered in to an agreement to acquire the worldwide rights to the molecular imaging research and development portfolio of Bayer.

Notably molecular imaging portfolio includes rights to florbetaben, that helps detect beta-Amyloid plaque deposition in the brain – an indication of probable ’s disease. It will result in earlier diagnosis and more specific treatment of Alzheimer’s disease.

Ajay Piramal Chairman of Piramal Group said “We plan to build a promising portfolio in the pharma space, including our newly acquired Molecular Imaging assets”